Abstract: Objective The aim of this study was to investigate the efficacy of Chinese herbal medicine compound,Fuzheng Huayu table, in the treatment of patients with hepatitis B-induced liver cirrhosis (LC) undergoing entecavir treatment. Methods 122 patients with hepatitis B-induced LC were enrolled in our hospital between August 2018 and December 2022, and were randomly divided into control (n=61) and observation (n=61) group, receiving entecavir or entecavir and Fuzheng Huayu table combination therapy for 52 weeks. Serum HBV DNA loads were detected by PCR, serum HBeAg and HBsAg levels were quantitatively assayed electrochemiluminescence, and liver stiffness measurement was determined by Fibroscan 502. Results At the end of 52 week treatment, serum HBV DNA negative rate in the observation group was 96.7%, not significantly different as compared to 93.4% in the control (P＞0.05), while serum ALT normalization rate was 98.4%, much higher than 85.2%(P＜0.05) in the control; serum HBsAg and HBeAg levels in the combination-treated group were (826.1±152.6)IU/mL and (194.5±33.8)IU/mL, both significantly lower than [(1005.3±207.5)IU/mL and (245.6±51.5)IU/mL, respectively, P＜0.05] in the control; serum ALT, AST and the LSM in the observation group were (49.6±7.3)U/L, (39.2±6.1)U/L and (9.2±2.1)kPa, all significantly lower than [(66.9±10.7)U/L, (52.8±8.7)U/L and (11.8±3.0)kPa, respectively, P＜0.05] in the control group. Conclusion The auxiliary oral administration of Fuzheng Huayu capsule at base of entecavir antiviral therapy might ameliorate liver fibrosis in patients with hepatitis B-induced LC, and is worthy of further clinical investigation.

Key words: Liver cirrhosis, Hepatitis B, Entecavir, Fuzheng Huayu capsule, herbal medicine, Liver stiffness measurement, Therapy